Idiopathic pulmonary fibrosis (IPF) is the most common progressive interstitial disease of
unknown etiology. The course of the disease cannot be predicted with certainty. It is crucial …

Background Although antifibrotic drugs, including nintedanib and pirfenidone, slow the
progression of idiopathic pulmonary fibrosis (IPF), there is little data about the timing of start …

Background and objective In clinical practice, a working diagnosis of IPF may be performed
to provide effective antifibrotic treatment to patients who cannot undergo SLB. In this study …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with poor survival.
Recent studies have improved understanding of IPF and new discoveries have led to novel …

Despite major research efforts leading to the recent approval of pirfenidone and nintedanib,
the dismal prognosis of idiopathic pulmonary fibrosis (IPF) remains unchanged. The …

Background The antifibrotic drugs nintedanib and pirfenidone reduce disease progression
in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching …

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has
been associated with a poor prognosis. However, the results of the INPULSIS and ASCEND …

Background Idiopathic pulmonary fibrosis (IPF) is a complex disease with a highly variable
clinical course and generally poor prognosis. Classified as a rare disease, significant …

In addition to idiopathic pulmonary fibrosis (IPF), other diffuse interstitial lung diseases (ILD)
are also associated with pulmonary fibrosis and occur in a variable proportion of patients …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia
of unknown cause that is associated with radiological and/or histological features of usual …